virogin biotech co.,ltd 2015.9. company introduction project introduction market analysismission and...
TRANSCRIPT
ViroGin Biotech Co.,LtdViroGin Biotech Co.,Ltd
2015.9
Company Introduction
Project Introduction
Market Analysis
Mission And Plan
1
2
3
4
CO
NTEN
TS
Company Introduction
Project Introduction
Market Analysis
Mission and plan
1
2
3
4
CO
NTEN
TS
Introduction of the companyIntroduction of the company
• Name of the company: ViroGin Biotech Ltd
(Registered in Cayman Islands)
•Including two operating centers:
•Shenzhen ViroGin Biotech Ltd (in China)
•Vancouver ViroGin Biotech Ltd (in Canada)
Background of the companyBackground of the company
• Virogin Biotech is an early stage Biotech research company.
• The company has a very advanced research team led by Dr. William
Jia. The team has completed many world class research projects.
Especially in the field of anti-tumor medicine with breakthrough
technology.
• In addition to their world class research team, the company also has
a very strong management team with investors and shareholders’
interest on top of their mind.
Target of the companyTarget of the company
• Virogin will focus on the research of anti-tumor medicine—the
research of cancer-dissolving virus vaccine---VGH-X. On target to
apply for the anti-tumor medicine patent within a year.
Furthermore, we are collecting all necessary data for the first stage
clinical test in two to three years and seeking CFDA approval.
Core MemberCore Member
Company Introduction
Project Introduction
Market Analysis
Target And Plan
1
2
3
4
CO
NTEN
TS
Project BackgroundProject Background
• What is an oncolytic virus ?
An oncolytic virus is a virus that specifically replicates in tumor cells
and causes tumor cell lysis but does not affect normal cells. The technology
of molecular virology makes the viral genome modification and recombination
possible. A few years ago the largest US biopharmaceutical company
AMGEN purchased with one billion dollars the herpes simplex virus (HSV-1)
based oncolytic virus from a small UK company (OncoVex) , and
successfully completed Phase III clinical trial in 2014. In April 2015 , the
joint meeting of the FDA’s Cellular, Tissue, and Gene Therapies Advisory
Committee (CTGTAC) and Oncologic Drugs Advisory Committee (ODAC)
voted at 22:1 to approve the biologics license for the drug (T-Vec), and made
it the first oncolytic viral drug in the world.
Project BackgroundProject Background
• Oncolytic virus and tumor vaccine
The rapidly advancing tumor immunotherapy is to use various means to
stimulate anti-tumor activities of immune cells as well as to block tumor-
induced immune suppression. Oncolytic virus clinical trials showed that the
anti-tumor activities of oncolytic viruses are not only due to the direct tumor
cell lysis caused by the viruses, but also due to virally induced anti-immune
response to the tumor.
Project BackgroundProject Background
• Advances of Technology - Virogin Biotech
The combination of oncolytic virus and immune therapy will produce a huge
synergy, especially for the treatments of solid tumors.
1. Oncolytic viruses infect a large number of tumor cells and present viral
antigens efficiently on tumor cells, which greatly help the activation and recognition
of immune cells.
2. Oncolytic tumor cell lysis caused by the virus releases a large number of
endogenous proteins, some of which may be tumor neoantigens and recognized
by the immune cells to attack surrounding uninfected cells.
Project BackgroundProject Background
• Advances of Technology - Virogin Biotech
3. Oncolytic virus infection of the tumor cells dramatically change the tumor
microenvironment, resulting in destruction of vascular structure and a large amount
of immune cell infiltration.
4. In current immunotherapies, blockers of tumor immunosuppressors are
injected to the entire body and therefore may produce toxic side effects. However
the blockers of immune suppression carried by oncolytic viruses are expressed in
tumors and can greatly reduce the toxic side effects.
Project DetailsProject Details
• Oncolytic virus tumor vaccine VGH-X carrying immune-stimulating factor(s)
• In vitro validation of VGH-X anti-tumor activity
• In vivo validation of VGH-X anti-cancer activity
Company Introduction
Project Introduction
Market Analysis
Target And Plan
1
2
3
4
CO
NTEN
TS
Analysis of the marketAnalysis of the market
1
Current status of the
market
2
Comparison with the
current oncotytic
product ONCOVEX
3
Comparison with
current immune-
therapy medicine
4
The price advantage
of our product
Many oncolytic viruses are in the clinical stage and the study of immunization therapy of PD1/PD-L1 is very popular; however, there has been no PD1/PDL1 blockers are expressed by OVs in the clinic.
Our product will have better intratumoural dissemination and the immune-stimulating factor will have much stronger immune stimulating effect; therefore, it should have better clinical result.
Curing effect will be better and the side effect will be much lower.
The producing cost will be similar to PD1/PD-L1 antibody; however, our product will have better curing power; therefore, our product will have price advantage.
Company Introduction
Project Introduction
Market Analysis
Target And Plan
1
2
3
4
CO
NTEN
TS
Target of financingTarget of financing
The creation of the company
1
2
3
4Completing the first run of financing before August 2015
Completing U$ 8million of the second run of financing before July 2016
Expansion of our operation
Introduction of our investorsIntroduction of our investors
Shen Zhen Sangel asset management limited is a comprehensive investment
institute which specializes in venture capital and angel capital projects; it is
incubator of high tech. companies. Sangel bases itself upon the most promising
industries: Biotech, Medical facilities, Healthcare, Technology of life resource,etc.
GP Capital investment fund management company is the manager of
Shanghai development investment fund which was founded by Shanghai
international asset management group, Jiangsu Sagang investment group, Huatai
security limited company and Hengdian holding company. On December 28th 2012,
the fund successfully closed its first close-end fund which was over 9 billion Ren
Ming Bi---Chinese Yuan.
Johnson & Johnson has been a part of people's lives for 129 years and a valuable part of
their investments for approximately 70 years. Founded in 1886, we listed our shares on the
New York Stock Exchange for public investors in 1944.
During our history, we have built the most comprehensive base of health care businesses
in the world, generating approximately 70 percent of our revenues from No. 1 or No. 2 glob
al leadership positions in our respective markets.
Over the last 10 years, Johnson & Johnson stock generated a 8.3 percent total return for
investors compared to a 7.7 percent total return for the S&P 500.
Development PlanDevelopment Plan
0-9months
9-12months
13-30months
31-50months
Completing the
construction of
the virus
Completing OV
virus
construction and
initial tests and
applying patents
Completing IND
enabling and
submitting IND
Completing Phase
I clinical trial
Thank Thank
YouYou !!Thank Thank
YouYou !!Virogin Biotech Co.,Ltd